A neuro-fuzzy security risk assessment system for software development life cycle.

Heliyon

Department of Computer Science, Faculty of Communication and Information Sciences, University of Ilorin, 240003, Kwara State, Nigeria.

Published: July 2024

This study aims to protect software development by creating a Software Risk Assessment (SRA) model for each phase of the Software Development Life Cycle (SDLC) using an Adaptive Neuro-Fuzzy Inference System (ANFIS) model. Software developers discovered and validated the risk variables affecting each SDLC phase, following which relevant data about risk factors and associated SRA for each SDLC phase were collected. To create the SRA model for SDLC phases, risk factors were used as inputs, and SRA was used as an output. The formulated model was simulated using 70 % and 80 % of the data for training, while 30 % and 20 % were used for testing the model. The performance of the SRA models using the test datasets was evaluated based on accuracy. According to the study findings, many risk variables were discovered and confirmed for the requirement, design, implementation, integration, and operation phases of SDLC 11, 8, 9, 4, and 6, respectively. The SRA model was formulated using the risk factors using 2048, 256, 512, 16, and 64 inference rules for the requirement, design, implementation, integration, and operation phases, respectively. The study concluded that using the SRA model to assess security risk at each SDLC phase provided a secured software development process.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11259873PMC
http://dx.doi.org/10.1016/j.heliyon.2024.e33495DOI Listing

Publication Analysis

Top Keywords

software development
16
sra model
16
sdlc phase
12
risk factors
12
risk
8
security risk
8
risk assessment
8
development life
8
life cycle
8
risk variables
8

Similar Publications

Background: The outcome of coronary artery bypass grafting (CABG) depends on several factors, including the quality of the distal anastomoses to the coronary arteries. Early graft failure may be caused by, e.g.

View Article and Find Full Text PDF

Background: Type 2 diabetes mellitus (T2D) remains a pressing public health concern. Despite advancements in antidiabetic medications, suboptimal medication adherence persists among many individuals with T2D, often due to the high cost of medications. To combat this issue, Blue Cross and Blue Shield of Louisiana (Blue Cross) introduced the $0 Drug Copay (ZDC) program, providing $0 copays for select drugs.

View Article and Find Full Text PDF

Introduction: The effectiveness of AZD7442 (tixagevimab/cilgavimab) against COVID-19 hospitalizations was determined at 3 and 6 months among immunocompromised individuals in Israel during different variant circulations.

Methods: This was a retrospective cohort study using data from Clalit Health Services in Israel. Immunocompromised individuals eligible to receive AZD7442 300 mg between 15 February and 11 December 2022 were identified.

View Article and Find Full Text PDF

Abnormal ac4C modification in metabolic dysfunction associated steatotic liver cells.

Sci Rep

January 2025

Department of Pharmacy, Affiliated Hospital of Southwest Jiao Tong University, The Third People's Hospital of Chengdu, Chengdu, 610014, China.

The pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear due to the complexity of its etiology. The emerging field of the epitranscriptome has shown significant promise in advancing the understanding of disease pathogenesis and developing new therapeutic approaches. Recent research has demonstrated that N4-acetylcytosine (ac4C), an RNA modification within the epitranscriptome, is implicated in progression of various diseases.

View Article and Find Full Text PDF

Objective Endometrial lesions are a frequent complication following breast cancer, and current diagnostic tools have limitations. This study aims to develop a machine learning-based nomogram model for predicting the early detection of endometrial lesions in patients. The model is designed to assess risk and facilitate individualized treatment strategies for premenopausal breast cancer patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!